U.S. Online Retail and Ecommerce Stock News

NasdaqGS:NFLX
NasdaqGS:NFLXEntertainment

Netflix (NFLX) Margin Strength Reinforces Bullish Narratives Despite Premium Valuation

Netflix FY 2025 Results in Focus Netflix (NFLX) has capped FY 2025 with fourth quarter revenue of US$12.1 billion and basic EPS of US$0.57, alongside trailing twelve month revenue of US$45.2 billion and basic EPS of US$2.58 that frame the latest numbers in a broader run of profitability. The company has seen quarterly revenue move from US$10.2 billion and basic EPS of US$0.44 in Q4 2024 to US$12.1 billion and US$0.57 in Q4 2025, while trailing net profit margins have been described at 24.3%...
NYSE:NSP
NYSE:NSPProfessional Services

Will Suspended European Tariffs And Rising Benefits Costs Change Insperity's (NSP) Narrative

Earlier this week, Insperity shares moved after President Trump suspended planned tariffs on European allies, easing immediate concerns about a transatlantic trade conflict and supporting broader market sentiment. The reaction highlights how macro policy shifts can temporarily boost confidence in companies like Insperity, even as they contend with slower revenue growth and rising benefits costs. We’ll now examine how relief over suspended European tariffs, alongside rising benefits costs,...
NYSE:PEN
NYSE:PENMedical Equipment

Assessing Penumbra (PEN) Valuation After Strong Recent Share Price Momentum

Why Penumbra Is On Investors’ Radar Right Now Penumbra (PEN) has recently caught attention after a period of strong share price moves, with the stock showing double digit returns over the past month and past 3 months. See our latest analysis for Penumbra. That recent surge fits into a wider upswing, with a 16.11% year to date share price return and a 31.09% total shareholder return over the past year suggesting momentum has been building rather than fading. If Penumbra has you rethinking your...
NYSE:CLF
NYSE:CLFMetals and Mining

Cleveland-Cliffs POSCO Pact And New Director Shape Valuation Outlook

Cleveland-Cliffs (NYSE:CLF) signed a memorandum of understanding with POSCO, setting the stage for a new partnership around operations and potential balance sheet benefits. The company also appointed Edilson Camara to its Board of Directors, adding fresh leadership experience to its governance structure. These developments arrive as investors assess Cleveland-Cliffs’ recent share performance and its positioning in the steel and mining space. Cleveland-Cliffs, trading at $15.09, has seen...
NasdaqCM:ATLO
NasdaqCM:ATLOBanks

Ames National (ATLO) Net Interest Margin Expansion Challenges Cautious Earnings Narratives

Ames National (ATLO) has just wrapped up FY 2025 with fourth quarter revenue of US$19.3 million and EPS of US$0.73, capping a trailing twelve month run of US$65.8 million in revenue and EPS of US$2.14 that coincides with 86.2% earnings growth and a net profit margin of 28.9% over the last year. The company has seen revenue move from US$53.5 million and EPS of US$1.14 on a trailing basis at the end of 2024 to the latest trailing totals, which may help provide a clearer picture of earnings...
NYSEAM:GORO
NYSEAM:GOROMetals and Mining

Assessing Gold Resource (GORO) Valuation After Silver Pivot And Record Don David Mine Performance

Gold Resource (GORO) is back in focus after a temporary work stoppage at its Don David mine in Oaxaca, driven by an illegal access blockade linked to a dispute among contractor affiliated union factions. See our latest analysis for Gold Resource. The recent contractor blockade comes after a period of strong share price momentum, with a 90 day share price return of 115.85% and a 1 year total shareholder return of 234.72%. However, the 5 year total shareholder return of a 40.59% decline shows...
NasdaqCM:AFBI
NasdaqCM:AFBIBanks

Affinity Bancshares (AFBI) Earnings Growth Challenges Cautious Narratives On Margin Durability

Affinity Bancshares (AFBI) has reported solid headline numbers for FY 2025 so far, with third quarter total revenue of US$8.3 million and basic EPS of US$0.35, supported by trailing twelve month revenue of US$31.8 million and EPS of US$1.19. Across the last few reported quarters, revenue has moved from US$7.4 million in Q4 2024 to US$7.8 million in Q1 2025, US$8.3 million in Q2 2025 and US$8.3 million in Q3 2025. Over the same stretch, quarterly EPS has gone from US$0.21 to US$0.29, US$0.34...
NasdaqGS:LAES
NasdaqGS:LAESSemiconductor

Why SEALSQ (LAES) Is Up 7.9% After India Quantum-Safe Chip Center JV Announcement – And What's Next

SEALSQ Corp and WISeKey’s subsidiary recently signed a non-binding Memorandum of Understanding with the Government of Gujarat and Kaynes SemiCon to collaborate on establishing India’s first secure semiconductor design, test, and personalization center focused on post-quantum cryptography at Sanand, targeting capacity of up to 300 million secure chips annually. This planned joint venture, SEALKAYNESQ Ltd, is intended to support India’s onshore, quantum‑resistant semiconductor ecosystem for...
NYSE:PRSU
NYSE:PRSUHospitality

Is Pursuit Attractions And Hospitality (PRSU) Pricing Reflect Recent Travel Demand Shifts Accurately

If you are wondering whether Pursuit Attractions and Hospitality is offering fair value at its recent price, this article walks through the numbers in a straightforward way so you can judge for yourself. The stock recently closed at US$35.25, with returns of 5.3% over the last 7 days, 2.9% over 30 days, 5.5% year to date, 22.8% over 3 years and a 9.1% decline over 1 year, which gives a mixed picture of recent and longer term performance. Outside of regular trading updates, investors have...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

Is STAAR Surgical (STAA) Attractively Priced After Prolonged Share Price Weakness?

If you are wondering whether STAAR Surgical's share price reflects its true value today, it helps to step back and look at how the market has been treating the stock recently. Over the last week, the share price return was 8.7% lower. The 30 day, year to date and 1 year returns were 18.0%, 18.9% and 21.7% lower respectively, and the 3 year and 5 year returns were 73.4% and 81.3% lower. This gives important context before judging any potential upside or downside. Recent coverage around STAAR...
NYSE:NATL
NYSE:NATLDiversified Financial

Is NCR Atleos (NATL) Pricing Look Stretched After Recent Spin Off Transition

If you are asking whether NCR Atleos at US$37.63 is a bargain, fully priced, or something in between, this article is going to walk you through the key signals that matter for valuation. The stock has moved around recently, with a 5.8% decline over the last 7 days, a 3.5% decline over the last 30 days, and returns of 1.1% year to date and 15.7% over the last year. Recent coverage has focused on NCR Atleos as a stand alone ATM and financial technology infrastructure business following its...
NasdaqGS:ADEA
NasdaqGS:ADEASoftware

Riverwater Partners Backs Adeia As Undervalued IP Licensing Opportunity

Riverwater Partners Sustainable Value Strategy has initiated a new position in Adeia Inc. (NasdaqGS:ADEA). The position reflects fresh institutional interest in Adeia's intellectual property business across media and semiconductor markets. Adeia focuses on licensing intellectual property that underpins media content distribution and semiconductor design, areas that remain central to how video is delivered and how chips are structured and manufactured. As streaming, connected devices and...
NasdaqCM:ARBE
NasdaqCM:ARBEElectronic

Assessing Arbe Robotics (ARBE) Valuation As Trading And Options Activity Surge

Arbe Robotics (ARBE) is attracting fresh attention after a sharp move in both its shares and options, with recent trading sessions showing concentrated call option activity and heavier volumes than the average month. See our latest analysis for Arbe Robotics. The latest options activity comes after a volatile stretch where the 7 day share price return of 49.12% and 30 day share price return of 65.05% contrast with a 1 year total shareholder return loss of 43.14%. This suggests short term...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story

Oruka Therapeutics, Inc. recently reported positive interim data from its first-in-human Phase 1 trial of ORKA-002, showing a long half-life, sustained IL-17 inhibition and a class-consistent safety profile in healthy volunteers, while outlining multiple ongoing and planned psoriasis and hidradenitis suppurativa studies across its ORKA-001 and ORKA-002 programs. A key insight for investors is the early clinical evidence suggesting ORKA-002 may enable twice-yearly maintenance dosing,...
NYSE:Q
NYSE:QSemiconductor

How Investors May Respond To Qnity Electronics (Q) Reaffirmed 2025 Sales Outlook And Interim CFO Appointment

Earlier this month, Qnity Electronics reaffirmed its full-year 2025 net sales guidance of about US$4.70 billion and announced that long-time finance executive Mike Goss will serve as Interim Chief Financial Officer following Matt Harbaugh’s health-related departure. The combination of steady guidance and a seasoned interim CFO, who brings nearly three decades of experience at DuPont and Ernst & Young, has sharpened investor focus on Qnity’s role as a newly independent supplier of...
NYSEAM:CMCL
NYSEAM:CMCLMetals and Mining

A Look At Caledonia Mining (NYSEAM:CMCL) Valuation After New Production Guidance, COO Exit And Convertible Financing

Caledonia Mining (CMCL) has packed a lot into its latest update, combining Q4 and full year 2025 production figures, fresh 2026 guidance, a COO departure, and new convertible bond financing. See our latest analysis for Caledonia Mining. Those production figures, new 2026 guidance, COO departure and fresh convertible notes have landed alongside a strong share price move. The 1 day share price return is 6.05%, the 7 day return is 15.36%, the 30 day return is 15.91% and the year to date return...
NasdaqCM:DVLT
NasdaqCM:DVLTSemiconductor

Is Datavault AI (DVLT) Turning Conference Visibility Into a Credible Real‑World Asset Tokenization Strategy?

Datavault AI Inc. recently presented at the ICR Conference 2026 in Orlando and is set to appear at the DealFlow Discovery Conference in Atlantic City, where CEO Nathaniel T. Bradley is discussing the company’s focus on real-world asset tokenization and broader technology portfolio. These conference appearances highlight Datavault AI’s effort to raise its profile with institutional investors and analysts by showcasing its tokenization strategy and long-term growth initiatives through formal...
NYSE:ASB
NYSE:ASBBanks

Associated Banc-Corp (ASB) Net Interest Margin Strength Tests Skeptical Profit Sustainability Narratives

Associated Banc-Corp (ASB) has wrapped up FY 2025 with fourth quarter revenue of US$382.4 million and basic EPS of US$0.81. Trailing twelve month revenue came in at US$1.43 billion with EPS of US$2.81. The company has seen revenue move from US$952.9 million and EPS of US$0.73 on a trailing basis at the end of 2024 to US$1.43 billion and EPS of US$2.81 by the end of 2025, setting the backdrop for what investors will focus on as potential rewards from reported growth forecasts and expanding...
NasdaqGS:AEVA
NasdaqGS:AEVAElectronic

Aeva Technologies (AEVA) Valuation Check As First Defense Contract With Forterra Expands 4D LiDAR Reach

Aeva Technologies (AEVA) has just secured its first defense sector contract, with Forterra selecting its 4D LiDAR sensors and perception technology for the AutoDrive autonomous vehicle system used in demanding mission environments. See our latest analysis for Aeva Technologies. The Forterra win lands after a busy start to the year, including Aeva’s new high power optical amplifier for AI data centers and its appearance at the Needham Growth Conference. Yet the share price has been volatile,...
NYSE:QXO
NYSE:QXOTrade Distributors

How QXO’s US$753 Million Follow-on Equity Raise At QXO (QXO) Has Changed Its Investment Story

In mid-January 2026, QXO, Inc. completed a follow-on equity offering of approximately US$753.16 million, issuing 31,645,570 common shares at US$23.80 each with a US$0.10 discount per share. This transaction forms part of a broader US$3 billion equity funding effort, signaling substantial financial backing for QXO’s acquisition-focused push in building products distribution and specialty contractor supply. With this sizeable equity raise underpinning its acquisition ambitions, we will examine...
NYSE:BKD
NYSE:BKDHealthcare

Is Brookdale Senior Living (BKD) Pricing Fully Reflecting Its Strong Multi Year Share Price Run?

If you are wondering whether Brookdale Senior Living's share price still offers value after a strong run, this article walks through what the current market price might be implying about the company. The stock last closed at US$12.95, with returns of 6.1% over 7 days, 18.9% over 30 days, 19.5% year to date, 163.2% over 1 year, 339.0% over 3 years, and 162.1% over 5 years, which has put it firmly on many investors' radar. Recent coverage around Brookdale Senior Living has focused on its...
NasdaqGS:LKFN
NasdaqGS:LKFNBanks

New Chief Credit Officer Appointment And What It Means For LKFN Investors

Lakeland Financial (NasdaqGS:LKFN) has appointed Donald J. Robinson-Gay as Executive Vice President and Chief Credit Officer of Lakeland Financial and Lake City Bank. The appointment places Robinson-Gay in charge of credit policy, loan portfolio oversight, and risk practices across the organization. Lakeland Financial, the parent of Lake City Bank, operates as a regional banking institution focused on serving business and retail clients through lending, deposit, and treasury services. For...
NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

A Look At Coherus Oncology (CHRS) Valuation After Its US$64.9 Million Follow On Equity Offering

Follow on offering sets the stage Coherus Oncology (CHRS) has filed a follow on equity offering of about US$64.9 million through an at the market program. This is a material move that directly affects funding plans and existing shareholders. See our latest analysis for Coherus Oncology. The follow on offering arrives after a sharp rebound in sentiment, with a 1 month share price return of 53.73% and year to date share price return of 50.37%. However, the 5 year total shareholder return of an...
NasdaqGS:CABA
NasdaqGS:CABABiotechs

Assessing Cabaletta Bio (CABA) Valuation After FDA Clearance For Automated CAR T Manufacturing

Cabaletta Bio (CABA) is back in focus after Cellares received FDA clearance for an IND amendment supporting automated manufacturing and quality testing of Cabaletta’s investigational CAR T therapy, rese cel, using Cell Shuttle and Cell Q platforms. See our latest analysis for Cabaletta Bio. The FDA clearance news arrives after a sharp shift in sentiment, with Cabaletta Bio’s 7 day share price return of 44.55% and 30 day return of 45.21% contrasting with a 3 year total shareholder return...